MarketPeel
Insider Trading Intelligence
MB

Munera Maria E. Bedoya-toro

DRMA
SVP, REGULATORY AFFAIRS · DERMATA THERAPEUTICS, INC. · CIK 0001400048
FILING MIX · LIFETIME67%/33%
BUYS
12
SELLS
6
TOTAL VALUE
$1.3K
COMPANIES
1
ACTIVE SINCE
Aug 2021
HOLDINGS NOW
1,012
AVG SELL PX
TRADE KIND
SHOWING 18 / 18
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
1 backtested trades · 8 horizons · 3 pending
Forward-return performance of every backtestable P/S trade by Munera Maria E. Bedoya-toro, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d1+0.00%-4.76%+0.66%-5.42%-5.42%
14d1+0.00%-7.54%-0.37%-7.17%-7.17%
30d1+0.00%-3.97%-3.38%-0.59%-0.59%
60d1+100.00%+7.94%+4.00%+3.94%+3.94%
90d1+0.00%-5.55%+8.71%-14.26%-14.26%
180d1(1 pending)
1y1(1 pending)
2y1(1 pending)
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
DRMA · 1,012 shares · as of Feb 17, 2026
021,03642,07263,10784,14320222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
FLOW · 12 buys / 6 sellsCOVERAGE · 19 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASE
SVP, Regulatory Affairs
1,000$1.27$1.3K1,012Feb 17, 2026Mar 17, 2026View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
9,0009,000Jan 2, 2026Jan 6, 2026View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
8,0008,000Jan 13, 2025Jan 14, 2025View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,00025,000Jan 4, 2024Jan 5, 2024View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
50,00050,000Jan 3, 2023Jan 5, 2023View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,00015,000Jan 3, 2022Jan 5, 2022View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASE
Senior Vice President
19,51248,186Aug 17, 2021Aug 17, 2021View →
DRMA
DERMATA THERAPEUTICS, INC.
SALE
Senior Vice President
100,0000Aug 17, 2021Aug 17, 2021View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASE
Senior Vice President
4,87853,064Aug 17, 2021Aug 17, 2021View →
DRMA
DERMATA THERAPEUTICS, INC.
SALE
Senior Vice President
400,0000Aug 17, 2021Aug 17, 2021View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASE
Senior Vice President
9,16228,674Aug 17, 2021Aug 17, 2021View →
DRMA
DERMATA THERAPEUTICS, INC.
SALE
Senior Vice President
61,8210Aug 17, 2021Aug 17, 2021View →
DRMA
DERMATA THERAPEUTICS, INC.
SALE
Senior Vice President
280,0000Aug 17, 2021Aug 17, 2021View →
DRMA
DERMATA THERAPEUTICS, INC.
SALE
Senior Vice President
100,0000Aug 17, 2021Aug 17, 2021View →
DRMA
DERMATA THERAPEUTICS, INC.
SALE
Senior Vice President
357,1420Aug 17, 2021Aug 17, 2021View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASE
Senior Vice President
13,65884,143Aug 17, 2021Aug 17, 2021View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASE
Senior Vice President
4,8784,878Aug 17, 2021Aug 17, 2021View →
DRMA
DERMATA THERAPEUTICS, INC.
PURCHASE
Senior Vice President
17,42170,485Aug 17, 2021Aug 17, 2021View →
Other insiders · DRMA
Loading peer insiders…
About this filer
CIK 0001400048
ROLE
SVP, Regulatory Affairs
PRIMARY
DRMA
COMPANIES
1
ACTIVE SINCE
Aug 2021
MARKETPEEL · /INSIDER/0001400048DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback